<?xml version="1.0" encoding="UTF-8"?>
<ref id="B20-jpm-11-00158">
 <label>20.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Buchanan</surname>
    <given-names>S.G.</given-names>
   </name>
   <name>
    <surname>Hendle</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>P.S.</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>C.R.</given-names>
   </name>
   <name>
    <surname>Bounaud</surname>
    <given-names>P.-Y.</given-names>
   </name>
   <name>
    <surname>Jessen</surname>
    <given-names>K.A.</given-names>
   </name>
   <name>
    <surname>Tang</surname>
    <given-names>C.M.</given-names>
   </name>
   <name>
    <surname>Huser</surname>
    <given-names>N.H.</given-names>
   </name>
   <name>
    <surname>Felce</surname>
    <given-names>J.D.</given-names>
   </name>
   <name>
    <surname>Froning</surname>
    <given-names>K.J.</given-names>
   </name>
  </person-group>
  <article-title>SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</article-title>
  <source>Mol. Cancer Ther.</source>
  <year>2009</year>
  <volume>8</volume>
  <fpage>3181</fpage>
  <lpage>3190</lpage>
  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0477</pub-id>
  <pub-id pub-id-type="pmid">19934279</pub-id>
 </element-citation>
</ref>
